The Latest Cardiac and Vascular News
— Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – — Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D. – — Strengthened Board of Directors with appointment […]
— Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease– — Small-diameter HAV observed to maintain patency and exhibit host-cell remodeling at six months post-implantation in a non-human primate model– –Results presented at American Heart Association Basic Cardiovascular Sciences Scientific Sessions 2022 […]
— HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma – — Immediately-available HAV, if approved, would represent significant and innovative advancements for vascular repair and replacement conduits– DURHAM, N.C., June 29, […]
Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, […]
— Successful first two HAV implantations in wounded Ukrainian citizens — HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort — Provides further real-world evidence of the potential of HAV treatment for trauma DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage […]
— Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure — — Data presented today in IMPACT session at American Transplant Congress (ATC) 2022 — DURHAM, N.C., June 08, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), […]
— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer — — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference […]
–Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle– –Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications– DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company […]
— Advancing late-stage clinical and preclinical programs of the Human Acellular Vessel™ (HAV™) and other engineered tissues across several indications – — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 am ET today – DURHAM, N.C., March […]
— Five-year data demonstrate the potential of the Human Acellular VesselTM (HAV) to be a durable and safe option for vascular access for routine, long-term hemodialysis — — Results published in EJVES Vascular Forum — DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing […]
